World Health Organization. Global Action Plan on AMR. https://apps.who.int/iris/handle/10665/193736. Accessed 20 Sept 2021.
O' Neill J. The review on antimicrobial resistance: tackling drug-resistant infections globally: final report and recommendations: https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf. Accessed 20 September 2021.
Impact of COVID-19 on people’s livelihoods, their health and our food systems. https://www.who.int/news/item/13-10-2020-impact-of-covid-19-on-people's-livelihoods-their-health-and-our-food-systems. Accessed 20 September 2021.
Nori P, Cowman K, Chen V, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. Infect Control Hosp Epidemiol. 2021;42:84–8.
Osman H, Nguyen P. First case of COVID-19 complicated with Burkholderia cepacia pneumonia and bacteremia. Chest. 2020;158:A544.
Rawson TM, Wilson RC, Holmes A. Understanding the role of bacterial and fungal infection in COVID-19. Clin Microbiol Infect. 2021;27:9–11.
Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021;27:520–31.
Sieswerda E, De Boer M, Bonten M, et al. Recommendations for antibacterial therapy in adults with COVID-19—An evidence based guideline. Clin Microbiol Infect. 2021;1:61–6.
García-Meniño I, Forcelledo L, Rosete Y, García-Prieto E, Escudero D, Fernández J. Spread of OXA-48-producing Klebsiella pneumoniae among COVID-19-infected patients: the storm after the storm. J Infect Public Health. 2021;14:50–2.
Mirzaei R, Goodarzi P, Asadi M, et al. Bacterial co-infections with SARS-CoV -2. IUBMB Life. 2020;72:2097–111.
Razazi K, Arrestier R, Haudebourg AF, et al. Risks of ventilator-associated pneumonia and invasive pulmonary aspergillosis in patients with viral acute respiratory distress syndrome related or not to Coronavirus 19 disease. Crit Care. 2020;24:699.
Council of Canadian Academies. When antibiotics fail: The expert panel on the potential socio-economic impacts of antimicrobial resistance in Canada. http://www.deslibris.ca/ID/10102747 Accessed 20 September, 2021).
World Health Organization. Antibiotic resistance. https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance. Accessed 20 September, 2021.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372: n71.
Covidence. Covidence - Better systematic review management. https://www.covidence.org/ Accessed 20 September, 2021.
Aromataris E, Munn Z. JBI manual for evidence synthesis. JBI. 2020. https://doi.org/10.46658/JBIMES-20-01.
Whiting PF. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529.
Guisado-Gil A, Infante-Domínguez C, Peñalva G, et al. Impact of the COVID-19 pandemic on antimicrobial consumption and hospital-acquired candidemia and multidrug-resistant bloodstream infections. Antibiotics. 2020;9:816.
Contou D, Claudinon A, Pajot O, et al. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. Ann Intensive Care. 2020;10:119.
Perez S, Innes GK, Walters MS, et al. Increase in hospital-acquired carbapenem-resistant Acinetobacter baumannii infection and colonization in an acute care hospital during a surge in COVID-19 admissions—New Jersey, February–July 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1827–31.
Sharifipour E, Shams S, Esmkhani M, et al. Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU. BMC Infect Dis. 2020;20:646.
Li J, Wang J, Yang Y, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. Antimicrob Resist Infect Control. 2020;9:153.
Salehi M, Ahmadikia K, Mahmoudi S, et al. Oropharyngeal candidiasis in hospitalised COVID-19 patients from Iran: Species identification and antifungal susceptibility pattern. Mycoses. 2020;63:771–8.
Mady A, Aletreby W, Abdulrahman B, et al. Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series. Ann Med Surg. 2020;60:417–24.
Bernardo CDO, Gonzalez-Chica D, Stocks N. Influenza-like illness and antimicrobial prescribing in Australian general practice from 2015 to 2017: a national longitudinal study using the MedicineInsight dataset. BMJ Open. 2019;9:e026396.
Russell CD, Fairfield CJ, Drake TM, et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe. 2021;2:e354–65.
Klein EY, Monteforte B, Gupta A, et al. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses. 2016;10:394–403.
Liu Y, Ling L, Wong SH, et al. Outcomes of respiratory viral-bacterial co-infection in adult hospitalized patients. EClinicalMedicine. 2021;37:100955.
Shah NS, Greenberg JA, McNulty MC, et al. Bacterial and viral co-infections complicating severe influenza: incidence and impact among 507 U.S. patients, 2013–14. J Clin Virol. 2016;80:12–9.
Gupta V, Yu KC, Kabler H et al. Antibiotic resistance patterns and association with the influenza season in the United States: A multicenter evaluation reveals surprising associations between influenza season and resistance in Gram-negative pathogens. Open For Infect Dis. 2022; ofac039. https://doi.org/10.1093/ofid/ofac039.
van Duin D, Barlow G, Nathwani D. The impact of the COVID-19 pandemic on antimicrobial resistance: a debate. J Antimicrob Resist. 2020; 2: dlaa053.
Chowdhary A, Tarai B, Singh A, Sharma A. Multidrug-resistant Candida auris infections in critically ill Coronavirus Disease patients, India, April–July 2020. Emerg Infect Dis. 2020;26:2694–6.
López-Jácome LE, Fernández-Rodríguez D, Franco-Cendejas R, Camacho-Ortiz A. Increment antimicrobial resistance during the COVID-19 pandemic: results from the Invifar Network. Microb Drug Resist. 2021. https://doi.org/10.1089/mdr.2021.0231.
Ramadan HK-A, Mahmoud MA, Aburahma MZ, et al. Predictors of severity and co-infection resistance profile in COVID-19 patients: first report from Upper Egypt. Infect Drug Resist. 2020; 13: 3409–22.
Vincent J-L, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe: results of the European prevalence of infection in intensive care (EPIC) study. JAMA. 1995;274:639–44.
Vincent J-L, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323–9.
Hanberger H, Garcia-Rodriguez JA, Gobernado M, et al. Antibiotic susceptibility among aerobic Gram-negative bacilli in intensive care units in 5 European countries. JAMA. 1999;281:67–71.
Frost I, Van Boeckel TP, Pires J, Craig J, Laxminarayan R. Global geographic trends in antimicrobial resistance: the role of international travel. J Travel Med. 2019;26:taz036.
Al-Maani A, Al Wahaibi A, Al-Zadjali N, et al. The impact of the hand hygiene role model project on improving healthcare workers’ compliance: A quasi-experimental observational study. J Infect Public Health. 2022;15:324–30.
Gallouche M, Terrisse H, Larrat S, et al. Effect of a multimodal strategy for prevention of nosocomial influenza: a retrospective study at Grenoble Alpes University Hospital from 2014 to 2019. Antimicrob Resist Infect Control. 2022;11:31.
Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26:1622–9.
Chang C-Y, Chan K-G. Underestimation of co-infections in COVID-19 due to non-discriminatory use of antibiotics. J Infect. 2020;81:e29-30.
Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020;81:266–75.
Clancy CJ, Nguyen MH. COVID19, superinfections and antimicrobial development: What can we expect? Clin Infect Dis. 2021;71:2736–43.
Bogossian EG, Taccone FS, Izzi A, et al. The acquisition of multidrug-resistant bacteria in patients admitted to COVID-19 intensive care units: A monocentric retrospective case control study. Microorganisms. 2020;8:1821.
Amarsy R, Pean de Ponfilly G r, Benmansour H a, Jacquier H, Cambau E e, Mégarbane B. Serratia marcescens outbreak in the intensive care unit during the COVID-19 pandemic: A paradoxical risk? Médecine Mal Infect. 2020; 50: 750–1.
Cataldo MA, Tetaj N, Selleri M, et al. Incidence of bacterial and fungal bloodstream infections in COVID-19 patients in intensive care: an alarming “collateral effect.” J Glob Antimicrob Resist. 2020;23:290–1.
Posteraro B, Torelli R, Vella A, et al. Pan-echinocandin-resistant Candida glabrata bloodstream infection complicating COVID-19: a fatal case report. J Fungi. 2020;6:163.
Mahmoudi H. Bacterial co-infections and antibiotic resistance in patients with COVID-19. GMS Hyg Infect Control. 2020;15:Doc35.
Mo Y, Adarkwah O, Zeibeq J, Pinelis E, Orsini J, Gasperino J. Treatment with tocilizumab for patients with COVID-19 infections: A case-series study. J Clin Pharmacol. 2021;61:406–11.
Walpole SC, McHugh R, Samuel J, Schmid ML. COVID-19 presenting as severe, persistent abdominal pain and causing late respiratory compromise in a 33-year-old man. BMJ Case Rep. 2020;13:e236030.
Montrucchio G, Corcione S, Sales G, Curtoni A, De Rosa FG, Brazzi L. Carbapenem-resistant Klebsiella pneumoniae in ICU-admitted COVID-19 patients: keep an eye on the ball. J Glob Antimicrob Resist. 2020;23:398–400.
Tiri B, Sensi E, Marsiliani V, et al. Antimicrobial stewardship program, COVID-19, and infection control: spread of carbapenem-resistant Klebsiella pneumoniae colonization in ICU COVID-19 patients. What did not work? J Clin Med. 2020;9:2744.
Kokkoris S, Papachatzakis I, Gavrielatou E, et al. ICU-acquired bloodstream infections in critically ill patients with COVID-19. J Hosp Infect. 2021;107:95–7.
Perrotta F, Perrini MP. Successful treatment of Klebsiella pneumoniae NDM sepsis and intestinal decolonization with ceftazidime/avibactam plus aztreonam combination in a patient with TTP complicated by SARS-CoV-2 nosocomial infection. Medicina (Mex). 2021;57:424.
Baiou A, Elbuzidi AA, Bakdach D, et al. Clinical characteristics and risk factors for the isolation of multi-drug-resistant Gram-negative bacteria from critically ill patients with COVID-19. J Hosp Infect. 2021;110:165–71.
Segrelles-Calvo G, Araújo GRS, Llopis-Pastor E, et al. Prevalence of opportunistic invasive aspergillosis in COVID-19 patients with severe pneumonia. Mycoses. 2021;64:144–51.
Martinez-Guerra BA, Gonzalez-Lara MF. Antimicrobial resistance patterns and antibiotic use during hospital conversion in the COVID-19 pandemic. Antibiotics (Basel). 2021;10:182.
Karruli A, Boccia F, Gagliardi M, et al. Multidrug-resistant infections and outcome of critically ill patients with Coronavirus Disease 2019: a single center experience. Microb Drug Resist. 2021. https://doi.org/10.1089/mdr.2020.0489.
Pulia MS, Wolf I, Schwei RJ et al. Antibiotic prescribing pattenrs for coronavirus diseas 2019 (COVID-19) in two emergency departments with rapid procalcitonin. Infect Control Hosp Epidemiol. 2020;1–3.
Gomez-Simmonds A, Annavajhala MK, McConville TH, et al. Carbapenemase-producing Enterobacterales causing secondary infections during the COVID-19 crisis at a New York City hospital. J Antimicrob Chemother. 2021;76:380–4.
Cultrera R, Barozzi A, Libanore M, et al. Co-infections in critically ill patients with or without COVID-19: a comparison of clinical microbial culture findings. Int J Environ Res Public Health. 2021;18:4358.
Khurana S, Singh P, Sharad N, et al. Profile of co-infections & secondary infections in COVID-19 patients at a dedicated COVID-19 facility of a tertiary care Indian hospital: Implication on antimicrobial resistance. Indian J Med Microbiol. 2021;39:147–53.
Pascale R, Bussini L, Gaibani P, et al. Carbapenem-resistant bacteria in an intensive care unit during the coronavirus disease 2019 (COVID-19) pandemic: a multicenter before-and-after cross-sectional study. Infect Control Hosp Epidemiol 2021: 1–6.
Baskaran V, Lawrence H, Lansbury LE, et al. Co-infection in critically ill patients with COVID-19: an observational cohort study from England: Read the story behind the paper on the Microbe Post here. J Med Microbiol. 2021. https://doi.org/10.1099/jmm.0.001350.
Moretti M, Van Laethem J, Minini A, Pierard D, Malbrain MLNG. Ventilator-associated bacterial pneumonia in coronavirus 2019 disease, a retrospective monocentric cohort study. J Infect Chemother. 2021;27:826–33.
Grasselli G, Scaravilli V, Mangioni D, et al. Hospital-acquired infections in critically ill patients with COVID-19. Chest. 2021;160:454–65.
Magnasco L, Mikulska M, Giacobbe DR, et al. Spread of carbapenem-resistant Gram-negatives and Candida auris during the COVID-19 pandemic in critically ill patients: One step back in antimicrobial stewardship? Microorganisms. 2021;9:95.
Bentivegna E, Luciani M, Arcari L, Santino I, Simmaco M, Martelletti P. Reduction of multidrug-resistant (MDR) bacterial infections during the COVID-19 pandemic: A retrospective study. Int J Environ Res Public Health. 2021;18:1003.
Suarez de la Rica A, Serrano P, de-la-Olivia R, Sahcez-Diaz P, Molinero P, Falces-Rmero I, Ferrado C, Rello J, Maseda E. Secondary infections in mechanically ventilated patients with COVID-10: An overlooked matter? Rev Esp Quimioter. 2021; 34: 330–336.
Posteraro B, De Angelis G, Menchinelli G, et al. Risk factors for mortality in adult COVID-19 patients who develop bloodstream infections mostly caused by antimicrobial-resistant organisms: analysis at a large teaching hospital in Italy. J Clin Med. 2021;10:1752.